dc.date.accessioned | 2024-04-08T16:20:02Z | |
dc.date.available | 2024-04-08T16:20:02Z | |
dc.date.created | 2024-03-21T11:02:55Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Johansson, Pär I. Fenger Eriksen, Christian Bovbjerg, Pernille E. Gaarder, Aslaug Christine Pall, Marlene Henriksen, Hanne Hee Pedersen, Kristine H Vigstedt, Martin Lange, Theis Næss, Pål Aksel Strømgaard Andersen, Mikkel Kirkegaard, Hans Stensballe, Jakob . Prostacyclin in trauma patients with hemorrhagic shock: A randomized clinical trial. Journal of Trauma and Acute Care Surgery. 2023, 96(3), 476-481 | |
dc.identifier.uri | http://hdl.handle.net/10852/110507 | |
dc.description.abstract | BACKGROUND
A main cause of trauma morbidity and mortality is multiple-organ failure, and endotheliopathy has been implicated. Pilot studies indicate that low-dose prostacyclin improves endothelial functionality in critically ill patients, suggesting that this intervention may improve trauma patient outcome.
METHODS
We conducted a multicenter, randomized, blinded, clinical investigator-initiated trial in 229 trauma patients with hemorrhagic shock who were randomized 1:1 to 72 hours infusion of the prostacyclin analog iloprost (1 ng/kg/min) or placebo. The primary outcome was the number of intensive care unit (ICU)–free days alive within 28 days of admission. Secondary outcomes included 28-day all-cause mortality and hospital length of stay.
RESULTS
The mean number of ICU-free days alive within 28 days was 15.64 days in the iloprost group versus 13.99 days in the placebo group (adjusted mean difference, −1.63 days [95% confidence interval (CI), −4.64 to 1.38 days]; p = 0.28). The 28-day mortality was 18.8% in the iloprost group versus 19.6% in the placebo group (odds ratio, 1.01 [95% CI, 0.51–2.0]; p = 0.97). The mean hospital length of stay was 19.96 days in the iloprost group versus 27.32 days in the placebo group (adjusted mean difference, 7.84 days [95% CI, 1.66–14.02 days], p = 0.01).
CONCLUSION
Iloprost did not result in a statistically significant increase in the number of ICU-free days alive within 28 days of admission, whereas it was safe and a statistically significant reduction in hospital length of stay was observed. Further research on prostacyclin in shocked trauma patients is warranted.
LEVEL OF EVIDENCE
Therapeutic/Care Management; Level II. | |
dc.language | EN | |
dc.publisher | Lippincott Williams & Wilkins | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Prostacyclin in trauma patients with hemorrhagic shock: A randomized clinical trial | |
dc.title.alternative | ENEngelskEnglishProstacyclin in trauma patients with hemorrhagic shock: A randomized clinical trial | |
dc.type | Journal article | |
dc.creator.author | Johansson, Pär I. | |
dc.creator.author | Fenger Eriksen, Christian | |
dc.creator.author | Bovbjerg, Pernille E. | |
dc.creator.author | Gaarder, Aslaug Christine | |
dc.creator.author | Pall, Marlene | |
dc.creator.author | Henriksen, Hanne Hee | |
dc.creator.author | Pedersen, Kristine H | |
dc.creator.author | Vigstedt, Martin | |
dc.creator.author | Lange, Theis | |
dc.creator.author | Næss, Pål Aksel | |
dc.creator.author | Strømgaard Andersen, Mikkel | |
dc.creator.author | Kirkegaard, Hans | |
dc.creator.author | Stensballe, Jakob | |
cristin.unitcode | 185,53,60,13 | |
cristin.unitname | Avdeling for traumatologi | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2256334 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Trauma and Acute Care Surgery&rft.volume=96&rft.spage=476&rft.date=2023 | |
dc.identifier.jtitle | Journal of Trauma and Acute Care Surgery | |
dc.identifier.volume | 96 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 476 | |
dc.identifier.endpage | 481 | |
dc.identifier.doi | https://doi.org/10.1097/TA.0000000000004150 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 2163-0755 | |
dc.type.version | PublishedVersion | |